Short Bowel Syndrome – SC403

Malabsorption in Short Bowel Sectioned Children – Many premature children develop issues with their digestive system requiring the re-sectioning of their small intestines. The damaged small intestine is removed and thereby a shorten bowel results. These children do not absorb food or nutrients. Hence, their growth is slowed and brain development may suffer. Many die.

There are several thousand cases of Short Bowel Syndrome (SBS) in children in the United States. Only a few thousand remain alive after birth and most die by age six. The estimated market for a drug capable of treating malabsorption is over $200,000,000.
Treatment options are limited, dangerous or off-label. There are no orally approved treatments for malabsorption in SBS.

Problem: There are no approved therapies for children with malabsorption related to SBS, an Orphan indication.

Current Treatment: IV Intralipid®, a known cause of liver disease in this population, is the only drug used to provide fatty acids to these children. IV must continue throughout life and normally results in liver damage.

ALT® Solution: ALT® formulation has been shown to restore circulating fatty acid levels, increase weight and reverse malabsorption. Data shows that near normal growth patterns develop in as little as five days after treatment with SC403.


Google+   Likedin